Rein Therapeutics’ (RNTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Rein Therapeutics (NASDAQ:RNTX) in a report issued on Tuesday, MarketBeat reports. HC Wainwright also issued estimates for Rein Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.47) EPS, FY2028 earnings at ($0.67) EPS, FY2029 earnings at ($0.58) EPS and FY2030 earnings at $0.56 EPS.

Several other equities research analysts also recently issued reports on RNTX. Weiss Ratings raised Rein Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 3rd. Maxim Group started coverage on shares of Rein Therapeutics in a research note on Monday, July 20th. They issued a “buy” rating and a $4.00 price target on the stock. Finally, Wall Street Zen raised shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $6.00.

Rein Therapeutics Stock Up 0.2%

NASDAQ:RNTX opened at $0.79 on Tuesday. The stock’s 50 day moving average price is $0.88 and its two-hundred day moving average price is $1.12. The firm has a market capitalization of $68.46 million, a price-to-earnings ratio of -0.46 and a beta of 1.39. Rein Therapeutics has a 12-month low of $0.69 and a 12-month high of $2.18.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.17. Equities research analysts expect that Rein Therapeutics will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Voss Capital LP increased its position in Rein Therapeutics by 59.2% during the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock worth $4,923,000 after buying an additional 1,577,437 shares during the period. Vanguard Group Inc. boosted its position in shares of Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after acquiring an additional 284,300 shares during the period. Cable Car Capital LP bought a new stake in shares of Rein Therapeutics in the second quarter valued at about $588,000. Sigma Planning Corp grew its stake in shares of Rein Therapeutics by 41.0% in the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock valued at $453,000 after acquiring an additional 101,400 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Rein Therapeutics by 15.1% during the fourth quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock worth $330,000 after acquiring an additional 37,244 shares during the period. 90.89% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Rein Therapeutics

Here are the key news stories impacting Rein Therapeutics this week:

• Positive Sentiment: The U.S. FDA granted Fast Track designation to LTI-03 for idiopathic pulmonary fibrosis (IPF). The designation recognizes the serious unmet need in IPF and could facilitate development, regulatory interactions, and review of the therapy. Rein said the Phase 2 RENEW trial is actively enrolling and remains on track to report interim data in the second half of 2026. Fast Track is not an approval, so upcoming clinical data remain the key catalyst. Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
• Positive Sentiment: HC Wainwright reiterated its Buy rating, while a separate report cited a $6.00 price target—well above recent trading levels. These views may provide valuation support, although analyst targets are forecasts rather than guarantees. HC Wainwright Reiterates Buy Rating for Rein Therapeutics Analysts Set Rein Therapeutics Price Target at $6.00
• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to a loss of $0.47 from a loss of $0.53, suggesting somewhat better near-term expectations and matching the broader annual forecast cited for the company.
• Neutral Sentiment: The same analyst modestly lowered projected losses for FY2028, FY2029, and fourth-quarter 2026, indicating that longer-term profitability expectations remain uncertain despite the continued Buy rating. The changes were small, with estimates still calling for losses through FY2029.
• Neutral Sentiment: Overall, the FDA milestone is the strongest near-term development for RNTX, while interim RENEW data expected in the second half of 2026 may determine whether the recent regulatory momentum translates into a sustained stock-price increase.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.